Taiwan Liposome Company Gross Profit

As of the most recent data (June 2021), TLC shows a gross profit of $280M. That compares with $55M in the prior-year period — up 406.1% year over year. That is below the Healthcare sector average of $66B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, TLC's gross profit is now $280M (was $55M) — a 406.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Taiwan Liposome Company is outperforming or lagging.

The Healthcare sector average gross profit is about $66B. Taiwan Liposome Company is at $280M, which is lower that average. That is roughly 99.6% below the sector mean. Use the comparison chart on this page to see how TLC stacks up against individual peers as well.

Tracking TLC's gross profit over time shows whether Taiwan Liposome Company is scaling, shrinking, or reshaping that part of the business. The current reading is $280M That compares with $55M in the prior-year period — up 406.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this gross profit page, Stockcircle has Taiwan Liposome Company's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect gross profit (currently $280M) with ownership activity and broader fundamentals.